Skip to content

Study · Systematic review · n = 207 · 2024

8 results

Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.

Dutta D, Nagendra L, Joshi A, Krishnasamy S, Sharma M, Parajuli N

Obesity surgery19 Mar 2024Cited by 34 (Europe PMC)

PMID38502519 (opens in a new tab)DOI10.1007/s11695-024-07175-8 (opens in a new tab)PepBankPUB-38502519
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, liraglutide gave significantly greater weight loss than placebo after 6 months of therapy (mean difference -6.0 kg).

    In plain wordsAfter bariatric surgery, patients on liraglutide lost more weight than patients on placebo after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss after 6 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean difference in weight loss
    −6 kg
    liraglutide vs placebo, 6 months

    Source sentences

    Summary
    Compared to placebo, patients receiving liraglutide had significantly greater weight loss after 6-month therapy [MD - 6.0 kg (95% CI, - 8.66 to - 3.33); P 2 = 79%].
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, liraglutide was associated with a significant decrease in fat mass (mean difference -4.78 kg).

    In plain wordsAfter bariatric surgery, liraglutide was linked to a decrease in body fat mass.

    Peptide
    Liraglutide
    Outcome
    DecreaseFat mass
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in fat mass
    −4.78 kg
    liraglutide

    Source sentences

    Summary
    A significant decrease in fat mass [MD - 4.78 kg (95% CI, - 7.11 to - 2.45); P < 0.001]
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  3. 03HumanSystematic reviewSafety outcome

    In patients after bariatric surgery, liraglutide was associated with a significant decrease in lean mass (mean difference -3.01 kg).

    In plain wordsAfter bariatric surgery, liraglutide was linked to a decrease in lean body mass.

    Peptide
    Liraglutide
    Outcome
    DecreaseLean mass
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Body weight · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean difference in lean mass
    −3.01 kg
    liraglutide

    Source sentences

    Summary
    lean mass [MD - 3.01 kg (95% CI, - 4.80 to - 1.22); P = 0.001]
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  4. 04HumanSystematic reviewSafety outcome

    In patients after bariatric surgery, liraglutide was associated with a significant decrease in whole-body bone mineral density (mean difference -0.02).

    In plain wordsAfter bariatric surgery, liraglutide was linked to a small decrease in whole-body bone mineral density.

    Peptide
    Liraglutide
    Outcome
    DecreaseWhole-body bone mineral density
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean difference in whole-body bone mineral density
    −0.02 kg/m<sup>2</sup>
    liraglutide

    Source sentences

    Summary
    whole-body bone mineral density [MD - 0.02 kg/m2 (95% CI, - 0.04 to - 0.00); P = 0.03] was noted with liraglutide.
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  5. 05HumanSystematic reviewEfficacy outcome

    In one study of patients after bariatric surgery, semaglutide had significantly higher rates of achieving more than 15% weight loss at 12 months.

    In plain wordsIn one study of people after weight-loss surgery, more people on semaglutide lost over 15% of body weight after 12 months.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieving more than 15% weight loss at 12 months
    Study

    n = 207

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    OR, >15% weight loss
    2.15
    12 months

    Source sentences

    Summary
    after 12-month therapy, semaglutide had significantly higher rates of achieving > 15% [OR 2.15 (95% CI, 1.07-4.33); P = 0.03; n = 207]
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  6. 06HumanSystematic reviewEfficacy outcome

    In one study of patients after bariatric surgery, semaglutide had significantly higher rates of achieving more than 10% weight loss at 12 months.

    In plain wordsIn one study of people after weight-loss surgery, more people on semaglutide lost over 10% of body weight after 12 months.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieving more than 10% weight loss at 12 months
    Study

    n = 207

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    OR, >10% weight loss
    2.1
    12 months

    Source sentences

    Summary
    In study by Murvelashvili et al. (2023), after 12-month therapy, semaglutide had significantly higher rates of achieving > 15% [OR 2.15 (95% CI, 1.07-4.33); P = 0.03; n = 207] and > 10% [OR 2.10 (95% CI, 1.19-3.71); P = 0.01; n = 207] weight loss.
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  7. 07HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, semaglutide gave a greater percent body weight reduction than liraglutide at 6 months.

    In plain wordsIn people after weight-loss surgery, semaglutide led to more weight loss than liraglutide after 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreasePercent body weight reduction at 6 months vs liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Percent weight reduction MD
    −2.57%
    6 months

    Source sentences

    Summary
    Compared to liraglutide, semaglutide had significantly greater percent reduction in body weight after 6-month [MD - 2.57% (95% CI, - 3.91 to - 1.23); P 2 = 0%]
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.
  8. 08HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, semaglutide gave a greater percent body weight reduction than liraglutide at 12 months.

    In plain wordsIn people after weight-loss surgery, semaglutide led to more weight loss than liraglutide after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreasePercent body weight reduction at 12 months vs liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Percent weight reduction MD
    −4.15%
    12 months

    Source sentences

    Summary
    Compared to liraglutide, semaglutide had significantly greater percent reduction in body weight after 6-month [MD - 2.57% (95% CI, - 3.91 to - 1.23); P 2 = 0%] and 12-month [MD - 4.15% (95% CI, - 6.96 to - 1.34); P = 0.004]
    2 context sentences
    Summary · context
    Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of GLP1RA in the intervention arm post-bariatric surgery.
    Summary · context
    From initially screened 1759 articles, 8 studies (557 individuals) were analysed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.